![\"ProNova](\"https:\/\/www.send2press.com\/wire\/images\/26-0623-s2p-pronova-ptrs-800x600.jpg\")
Image caption: ProNova Partners, Inc.<\/em><\/p>\n
The platform lets a person measure their own vision with a smartphone and receive a doctor-generated eyeglass or contact lens prescription remotely, without a clinic visit. It spans seven FDA-registered medical devices and applications, and independent clinical trials have confirmed accuracy comparable to the in-office equipment used in a traditional eye exam.<\/p>\n
More than 50,000 devices are in use across over 150 countries, built up over eight years of operation with zero product defects and zero litigation. The technology, while not meant to replace the traditional in-clinic eye exam, carries a full regulatory and quality stack, including ISO 13485 and HIPAA compliance, and is protected by more than two dozen issued patents.<\/p>\n
\u201cEvery so often a technology quietly solves a problem an entire industry has worked on for decades,\u201d said Terie Salinas, Chief Operating Officer of ProNova Partners. \u201cThis is one of those. It is fully built, clinically validated, and already in use worldwide. Our mandate is to bring the right strategic partners to it.\u201d<\/p>\n
The technology arrives as the roughly $60-billion U.S. vision-care market faces a growing shortage of eye-care providers, and as the traditional eye exam \u2014 essentially unchanged for two centuries \u2014 becomes the next consumer-health category reshaped by telehealth and artificial intelligence.<\/p>\n
\u201cWe have completed more than 500 transactions across many arenas, including the medical-device, healthcare, and technology space,\u201d Salinas said. \u201cThat is exactly the experience a platform like this requires.\u201d<\/p>\n
Company details are available to qualified parties upon execution of a standard non-disclosure agreement.<\/p>\n
For detailed information go to https:\/\/pronovapartners.com\/engagement\/patented-at-home-vision-testing-platform-for-sale\/<\/a><\/p>\n